Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, discusses the potential of calreticulin-directed vaccines in the treatment of myeloproliferative neoplasms (MPNs). Prof. Kiladjian first explains the mechanism of action of these vaccines and then goes on to explain the need to further explore their potential application in the field. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.
Негізгі бет Calreticulin-directed vaccines how they may impact MPN treatment
No video
Пікірлер